글로벌 전자 약물 전달 시스템 시장 – 2030년까지의 산업 동향 및 예측

전자 약물 전달 시스템 시장 분석 및 규모

표적 질병의 유병률 증가는 글로벌 전자 약물 전달 시스템 시장 성장을 가속화하는 주요 요인입니다. 나아가 주요 시장에서의 유리한 환급 시나리오, 기술 및 디자인의 급속한 발전, 다양한 만성 질환의 유병률 증가, 노인 환자 풀의 증가도 전자 약물 전달 시스템 시장 성장을 촉진할 것으로 예상됩니다.

Data Bridge Market Research는 2022년에 16,139.89백만 달러였던 글로벌 전자 약물 전달 시스템 시장이 2030년까지 17,576.34백만 달러로 급증할 것이며, 2023-2030년 예측 기간 동안 8.9%의 CAGR을 보일 것으로 분석했습니다. 이는 시장 가치가 "전자 주입 펌프"가 다양한 만성 질환 치료에 전자 주입 펌프에 대한 수요가 증가함에 따라 글로벌 전자 약물 전달 시스템 시장의 유형 세그먼트를 지배하고 있음을 나타냅니다. 시장 가치, 성장률, 세분화, 지리적 범위 및 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

전자 약물 전달 시스템 시장 범위 및 세분화

시장 정의

전자 약물 전달 시스템은 기본적으로 전자적으로 활성화되어 있으며, 스마트 약물 전달 장치는 가정 간병 환경에 적합합니다. 이러한 장치는 오래된 도구에 가치를 더하고 투여의 용이성, 적합성 및 이동성을 증가시킵니다.            

글로벌 전자 약물 전달 시스템 시장 역학

운전자

• 만성 질환의 증가

당뇨병, 천식, 심혈관 질환과 같은 만성 질환의 유병률은 전 세계적으로 증가하고 있습니다. 전자 약물 전달 시스템은 정확하고 통제된 약물 투여를 제공하여 만성 질환을 효과적으로 관리하는 데 필수적입니다.

• 환자 편의성 및 규정 준수

전자 약물 전달 시스템은 환자에게 약물을 투여하는 데 더 사용자 친화적이고 편리한 옵션을 제공합니다. 이는 이러한 시스템에 종종 알림 및 추적 기능이 포함되어 환자가 처방대로 약물을 복용하도록 보장하므로 환자의 준수성이 향상될 수 있습니다.

• 기술의 발전 

Advances in electronics and microtechnology have enabled the development of sophisticated electronic drug delivery devices. These devices can accurately control dosage, monitor usage, and connect with healthcare providers through mobile apps and cloud-based platforms, enhancing treatment outcomes.

• Growing Investment for Healthcare Facilities

Surging focus towards improving the condition of healthcare facilities and improving the overall healthcare infrastructure another important factor fostering the growth of the market. Rising number of partnerships and strategic collaborations between the public and private players pertaining to funding and application of new and improved technology is further creating lucrative market opportunities.  

Opportunities

• Rise in Biologics and Gene Therapies

The rise of biologics and gene therapies necessitates precise and controlled drug delivery methods. Electronic drug delivery systems can play a crucial role in administering these complex therapies accurately. As the development and adoption of biologics and gene therapies increase, there is a growing opportunity for electronic drug delivery devices in this segment.

• Emerging Markets

Electronic drug delivery systems are becoming more accessible in emerging markets. As these markets continue to grow and healthcare infrastructure improves, there is a significant opportunity for companies to expand their presence and offer innovative electronic drug delivery solutions to meet the healthcare needs of these populations.

Restraints/ Challenges

• High Cost of Development and Adoption

Developing and manufacturing electronic drug delivery systems can be expensive due to the need for advanced technology, materials, and regulatory compliance. Additionally, healthcare providers and patients may face high initial costs when adopting these systems, limiting their widespread adoption, particularly in resource-constrained healthcare systems.

• Stringent Regulatory Requirements

The regulatory approval process for electronic drug delivery systems can be complex and time-consuming. Meeting the rigorous safety and efficacy standards set by regulatory authorities such as the FDA in the United States can significantly delay market entry and increase development costs.

• Limited Patient Acceptance and Training

Electronic drug delivery systems often require patients to learn how to use these devices properly. Patients, especially the elderly or those with limited technical proficiency, may be reluctant to adopt new technologies or find it challenging to use electronic drug delivery systems correctly. This can impact patient compliance and acceptance.

• Data Privacy and Security Concerns

Connected electronic drug delivery systems that transmit patient data and usage information raise concerns about data privacy and security. Healthcare providers and patients may be hesitant to use these systems if they perceive risks related to data breaches or unauthorized access to sensitive medical information.

This global electronic drug delivery systems market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global electronic drug delivery systems market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In June 2022, Gufic Biosciences Ltd launched a new drug delivery system, Dual Chamber Bags, at affordable prices for the first time in India
• In February 2022, Takeda received US FDA approval for TAKHZYRO (lanadelumab-flyo) injection in a single-dose prefilled syringe (PFS), which is used to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older

Global Electronic Drug Delivery Systems Market Scope

The global electronic drug delivery systems market is segmented on the basis of type, component, connectivity, system type, application, and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Electronic infusion pumps
• Electronic injection pens
• Electronic auto-injectors
• Electronic inhalers
• Electronic capsules
• Others

Component

• Sensors
• Wireless communicator and antennas
• Micro pumps and flow regulators
• Drug reservoir
• Microcontroller
• Others

Connectivity

• Bluetooth low energy (BLE)
• Wi-Fi
• Ethernet
• NB-IoT
• Others

System Type

• Battery-powered systems
• Rechargeable systems

Application

• Diabetes
• Asthma
• Chronic obstructive pulmonary disease (COPD)
• Multiple sclerosis
• Growth hormone therapy
• Immunodeficiency disease
• Cardiovascular disease
• Thalassemia
• Others

End User

• Hospitals
• Clinics
• Ambulatory centers
• Home healthcare
• Others

Global Electronic Drug Delivery Systems Market Regional Analysis/Insights

The global electronic drug delivery systems market is analysed and market size insights and trends are provided by country, type, component, connectivity, system type, application, and end user as referenced above.

The countries covered in the global electronic drug delivery systems market report are U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa.

North America dominates the global electronic drug delivery systems market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period 2023-2030. This is due to increment in electronic infusion pump on a large scale. Asia-Pacific on the other hand is projected to exhibit the highest growth rate during the forecast period due to the growing incidence of asthma and heart disease with the development of the pharmaceutical industry.  

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.    

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The global electronic drug delivery systems market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for global electronic drug delivery systems market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the global electronic drug delivery systems market. The data is available for historic period 2015-2020.

Competitive Landscape and Global Electronic Drug Delivery Systems Market Share Analysis

The global electronic drug delivery systems market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global electronic drug delivery systems market.

Some of the major players operating in the global electronic drug delivery systems market are:

• AstraZeneca (U.K.)
• Amgen Inc. (U.S.)
• Ypsomed AG (Switzerland)
• 머크 KGaA(미국)
• Bayer AG(독일)
• 네메라(프랑스)
• F. 호프만-라 로슈 유한회사(스위스)
• Teva Pharmaceuticals USA, Inc. (미국)
• AptarGroup, Inc. (미국)
• Novo Nordisk A/S. (덴마크)
• ViCentra BV(네덜란드)
• 메드트로닉(미국)
• 유나이티드 테라퓨틱스 코퍼레이션(미국)
• 컴패니언 메디컬(미국)
• Tandem Diabetes Care, Inc. (미국)
• 데비오텍 SA(스위스)
• Canè SpA(이탈리아)
• 인슐렛 코퍼레이션(미국)
• BD(미국)
• B. Braun Melsungen AG(독일)

SKU-50456